Method of immunotherapy for treatment of human papillomavirus infection
A method of treating human papillomavirus (HPV), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and inducing an immune response to HPV. A method of overcoming HPV-induced immune suppression of Langerhans cells (LC), by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, and activating LC. A method of increasing LC migration towards lymph nodes, by administering a therapeutically effective amount of a primary cell-derived biologic to a patient infected with HPV, activating LC, and inducing LC migration towards lymph nodes. A method of generating immunity against HPV, by administering an effective amount of a primary cell derived biologic to a patient infected with HPV, generating immunity against HPV, and preventing new lesions from developing.
1. A method of immunotherapy for treating a viral infection caused by human papillomavirus (HPV) in a patient, comprising:
administering an effective amount of a primary cell-derived biologic to a patient having a viral infection caused by HPV in order to alleviate or eliminate the infection, such that an immune response is induced to the HPV in the patient which does alleviate or eliminate the infection, and wherein the primary cell-derived biologic comprises the cytokines interleukin (IL)-1, interleukin (IL)-2, interleukin (IL)-6, interleukin (IL)-8, interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha.
2. The method of claim 1 , wherein the primary cell-derived biologic includes a concentration of IL-1 from 60-6,000 pcg/mL, a concentration of IL-2 from 600-60,000 pcg/mL, a concentration of IL-6 from 60-6,000 pcg/mL, a concentration of IL-8 from 6000-600,000 pcg/mL, a concentration of TNF-alpha from 200-20,000 pcg/mL, and a concentration of IFN-gamma from 200-20,000 pcg/mL.
3. The method of claim 1 , wherein the primary cell-derived biologic further comprises interleukin (IL)-7, interleukin (IL)-12, interleukin (IL)-15, granulocyte-macrophage colony-stimulating factor (GM-CSF), and granulocyte colony-stimulating factor (G-CSF).
4. The method of claim 3 , wherein the primary cell-derived biologic includes a concentration of IL-7 from 100-10,000 pcg/mL, a concentration of IL-12 from 100-10,000 pcg/mL, a concentration of IL-15 from 100-10,000 pcg/mL, a concentration of GM-CSF from 100-10,000 pcg/mL, and a concentration of G-CSF from 100-10,000 pcg/mL.
5. The method of claim 1 , wherein the method further comprises:
administering an effective amount of one or more of a chemical inhibitor, a non-steroidal anti-inflammatory drug (NSAID), and zinc to the patient.
6. The method of claim 5 , wherein the chemical inhibitor is cyclophosphamide.
7. The method of claim 5 , wherein the NSAID is indomethacin.
8. The method of claim 1 , wherein the primary cell-derived biologic is in a sterile, injectable solution.
9. The method of claim 1 , wherein the administering of the primary cell-derived biologic is injection into the patient's epithelium.
10. The method of claim 1 , wherein the administering of the primary cell-derived biologic is topical application to the patient's epithelium.
11. The method of claim 1 , wherein administration of the primary cell-derived biologic prevents new HPV-induced lesions from developing.
12. The method of claim 1 , wherein the patient has not received surgery, radiotherapy, chemotherapy, or combinations thereof, prior to administration of the primary cell-derived biologic.
13. The method of claim 1 , wherein the patient is a man.
14. The method of claim 13 , wherein the patient does not have cancer.
15. The method of claim 1 , wherein the patient is a woman.
16. The method of claim 15 , wherein the patient does not have cancer.